ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1592734
Predictive Value of Serum Interleukin-33 and Thymic Stromal Lymphopoietin for the Risk of Acute Exacerbation in Patients with Chronic Obstructive Pulmonary Disease
Provisionally accepted
- 1Department of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Anhui Medical University, Hefei, China
- 2Anhui Institutes for Food and Drug Control, Hefei, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) lacks reliable biomarkers. This study aimed to explore the predictive value of serum interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) for acute exacerbations of COPD (AECOPD). Methods: This retrospective study included patients with stable-phase COPD between June 2023 and June 2024 at the Third Affiliated Hospital of Anhui Medical University. Patients were assigned to the low-risk and high-risk groups according to the number and severity of AECOPD events. Multivariable logistic regression analysis was used to identify the factors of AECOPD risk. Receiver operating characteristic (ROC) curves were used to assess the predictive value of IL-33 and TSLP for AECOPD risk. Results: A total of 76 patients were enrolled, with 33 in the low-risk group and 43 in the high-risk group. Serum IL-33 (835.30 vs. 770.30, P=0.008) and TSLP (102.20 vs. 90.45, P<0.001) levels were higher in the high-risk group than in the low-risk group. Serum TSLP (odds ratio (OR)=1.095, 95% confidence interval (CI): 1.013-1.184, P=0.022) was independently associated with AECOPD. The area under the curve (AUC) for IL-33 in predicting AE was 0.677 (95%CI: 0.554-0.801), with 93.0% sensitivity and 39.4% specificity. The AUC for TSLP was 0.768 (95%CI: 0.659-0.878), with 76.7% sensitivity and 72.7% specificity. Combined prediction using IL-33 and TSLP yielded an AUC of 0.779 (95%CI: 0.669-0.888), with 81.4% sensitivity and 72.7% specificity. Conclusion: High serum TSLP might be associated with an increased risk of AECOPD. While IL-33 alone showed high sensitivity and low specificity, its potential predictive value may be worth exploring.
Keywords: chronic obstructive pulmonary disease, Acute exacerbation, interleukin-33, thymic stromal lymphopoietin, risk prediction
Received: 13 Mar 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 Yin, Xu, Shi, Liu and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hua Liu, Anhui Institutes for Food and Drug Control, Hefei, China
Zhen Ding, Department of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Anhui Medical University, Hefei, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.